[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parkinson-disease-idiopathic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parkinson-disease-idiopathic":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,57,87,117,147,174,203,231,255,281,309,334,359,383,406],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100568408","phase-2-a-phase-2-study-and-open-label-extension-of-neu-411-in-companion-diagnostic-positive-participants-with-early-parkinsons-disease-100568408",false,"NCT06680830","A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)","NEULARK","Inclusion Criteria:\n\n1. Aged 40-80 years at time of screening, inclusive\n2. Diagnosis of clinically established or clinically probable Parkinson's Disease (PD)\n3. LRRK2-driven PD using the investigational companion diagnostic genetic test (CDx)\n4. Modified Hoehn and Yahr (mH\\&Y) of 1 to 2.5\n\nExclusion Criteria:\n\n1. Secondary or atypical parkinsonian syndromes\n2. Uncontrolled diabetes mellitus with hemoglobin A1c (HbA1c) \\>8%\n3. Other significant medical conditions (as determined by medical history, examination, or clinical investigations at screening)\n\nAdditional inclusion and exclusion criteria for the RCP and OLE are outlined in the full study protocol.","ALL","40 Years","80 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the \"leucine-rich repeat kinase 2\" (\"LRRK2\" for short) pathway based on their genetic profile. A DNA test will be used to identify the \"LRRK2-driven\" population with predicted elevation in the LRRK2 pathway.",[28,29,30,31,32],"Parkinson Disease","Parkinson","Idiopathic Parkinson Disease","Early Parkinson Disease (Early PD)","Parkinson Disease, Idiopathic",[34,35,36,37,38,39,15,40,41,42,43],"Early PD","Parkinsons","Parkinsons Disease","Idiopathic Parkinsons Disease","leucine-rich repeat kinase 2","PD","LRRK2","PARK8","de novo Parkinsons disease","Parkinson's disease","RECRUITING","2026-06-29",{"date":47,"type":48},"2026-07-01","ACTUAL",{"date":50,"type":48},"2025-01-17",{"date":52,"type":22},"2028-06",{"name":54,"class":55},"Neuron23 Inc.","INDUSTRY",70,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":17,"minAge":66,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100637518","aid-fog-artificial-intelligence-driven-freezing-of-gait-detection-in-the-home-100637518","NCT07580612","AID-FOG: Artificial Intelligence-Driven Freezing of Gait Detection in the Home","Artificial Intelligence-Driven Freezing Of Gait Detection in the Home: Investigating How Free-living Activities Affect the Algorithm","AID-FOG","Inclusion Criteria:\n\nFor all participants\n\n* Voluntary written informed consent of the participant has been obtained prior to any study-related procedures, except the non-recorded pre-screening questions;\n* At least 18 years of age at the time of signing the Informed Consent Form (ICF);\n* Person is cognitively able to follow and understand instructions and provide voluntary written informed consent;\n* Person is able to walk for short distances (± 10 meters) independently, with- or without use of a walking aid;\n* Person does not live in a temporary or permanent care facility.\n\nFor participants with PD:\n\n* Clinical diagnosis of Parkinson's disease (PD) made by a neurologist according to the Movement Disorders Society guidelines;\n* Person self-reports to experience daily FOG (for recruitment of freezers only);\n* Person is willing to temporarily delay the morning anti-Parkinsonian medication during the standardized assessment visit.\n\nExclusion criteria:\n\n* Occurrence of any of the following within 3 months prior to informed consent: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), implantation of a cardiac resynchronization therapy device (CRTD), active treatment for cancer or other malignant disease, uncontrolled congestive heart disease (NYHA class \\>3), acute psychosis or major psychiatric disorders or continued substance abuse, other neurological (than PD) or orthopaedic impairment that significantly impacts on gait;\n* Participant self-reports daily falls;\n* Participation in another interventional study, with or without an investigational medicinal product (IMP) or device (IMD)",true,"18 Years",{"count":68,"type":22},126,"OBSERVATIONAL","Freezing of gait (FOG) is a debilitating symptom of Parkinson's disease increases the risk of falling. Despite being a common symptom, it is still difficult to evaluate freezing of gait quickly and accurately. Currently, the gold-standard method to determine the severity of FOG is a manual analysis of video footage by an experienced assessor, collected during standardized FOG-provoking walking tests. Because this is a very time-intensive process, where different assessors sometimes obtain different results, our team at KU Leuven have developed an artificial-intelligent (AI) algorithm trained to identify FOG episodes based on wearable inertial measurement unit (IMU) sensor data. The AI algorithm has already undergone initial validation during laboratory testing, yielding promising results. The aim of this study is to investigate whether the AI algorithm can accurately detect FOG episodes in a less controlled environment, namely the home environment. In a second phase, the investigators will also use the collected data to improve the AI algorithm for automated FOG detection in the home. Finally, the investigators want to explore whether the AI algorithm can detect FOG in real-time.",[32,72,73,74,75],"Freezing of Gait","Validation","Wearable Sensors","Artifical Intelligence","2026-05-05",{"date":78,"type":48},"2026-05-12",{"date":80,"type":48},"2025-09-22",{"date":82,"type":22},"2027-06",{"name":84,"class":85},"KU Leuven","OTHER",3,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100584625","investigating-adaptive-deep-brain-stimulation-in-parkinsons-disease-management-100584625","NCT06891781","Investigating Adaptive Deep Brain Stimulation in Parkinson's Disease Management","A Prospective, Multi-center, Randomized, Double-blind, Cross Over, Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Stimulation in Levodopa- Responsive Parkinson's Disease Treated With Bilateral Deep Brain Stimulation of the Subthalamic Nucleus","ADVENT","INCLUSION CRITERIA\n\nSubjects who meet all of the following criteria may be given consideration for inclusion in this clinical trial:\n\n1. Is willing and capable of signing informed consent\n2. Is ≥18 years old\n3. Has been diagnosed with levodopa-responsive idiopathic Parkinson's disease\n4. Has a Hoehn and Yahr (H\\&Y) scale stage of II or III when OFF medication at screening\n5. Exhibits motor fluctuations and PD-related symptoms that are not adequately controlled with medication, including motor complications of recent onset (\\>4 months duration)\n6. Has been referred for bilateral STN DBS in accordance with local practice\n7. Must be a good surgical candidate for placement of a deep brain stimulator as judged by the DBS surgical team\n8. Montreal Cognitive Assessment (MoCA) score of ≥ 26 at the Baseline\u002FScreening visit (when in \"MedsON\" state)\n9. UPDRS-III improvement by ≥30% with the levodopa challenge test as measured at approximately 90 minutes following administration of the challenge dose\n10. ≥4 hours per day (waking hours) with poor motor symptoms control (time \"OFF\" plus time \"ON\" with dyskinesia) despite optimal medical therapy, as assessed by the 3-day diary (at preop baseline)\n11. Subject successfully completed a test diary reaching a sufficient level of agreement (\\>75%) with study personnel responses and is willing and capable of completing a 3-day diary at each of the time points required per the protocol\n12. If female, subjects who are not currently pregnant as determined by negative serum pregnancy test, breastfeeding, or who are post-menopausal, surgically sterile or willing to use birth control for the duration of the study (acceptable forms of birth control are: hormone therapies (oral, injected, transdermal or implanted), IUD or other barrier methods (e.g., condom, diaphragm, cervical cap, spermicide\u002Fgel) or partner is surgically sterile\n13. Subject maintained a constant anti-PD medication treatment (best medical management, as duly documented) for at least 2 weeks prior to Baseline assessments\n14. Subject is willing and able to attend all study-required visits, complete the study procedures and attend appropriate follow up visits\n\nEXCLUSION CRITERIA\n\nThe subject must not meet any of the following exclusion criteria:\n\n1. Has contraindications for DBS surgery, including any intracranial abnormality (e.g., generalized atrophy, vascular malformation, hydrocephalus, hematoma, cavernous or venous angioma, tumor or metastases, midline shift, etc.) or metallic implant (e.g., aneurysm clip, cochlear implant, etc.) or other clinically significant space-occupying lesion which in the opinion of the surgeon would impact the ability to target and place the leads or IPG\n2. Is not on a stable dose of levodopa anti-Parkinson's disease medication for at least 2 weeks prior to Screening\u002FBaseline assessments\n3. Has any current major psychiatric disorder(s), such as Major Depressive Disorder, Bipolar I or II disorder, Schizophrenia, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Obsessive-Compulsive Disorder, or any other current psychiatric condition that in the opinion of the investigator would confound the assessment of study endpoints, prevent proper data collection and\u002For compromise the subject's ability to participate, based on the psychiatric\u002Fpsychological assessment at screening.\n\n   (It is permitted if a subject has a diagnosis of Major Depressive Disorder with symptoms that currently are well-controlled and managed by a stable regimen of antidepressants for a minimum of 4 weeks prior to the screening visit). Includes current moderate or severe alcohol and\u002For substance use disorder based on the psychiatric\u002Fpsychological assessment at screening.\n4. A history of suicide attempt within 3 years of the screening visit or current active suicidal ideation as determined by a psychiatric\u002Fpsychological evaluation\n5. Any medical condition, such as cognitive impairment, dementia, seizures, congestive heart failure, unstable angina, uncontrolled diabetes, renal failure requiring dialysis, or any other severe medical condition that could interfere with study procedures, confound the assessment of study endpoints, prevent proper data collection, or that, in the opinion of the investigator, would compromise the subject's ability to participate\n6. Confirmation of diagnosis of a terminal illness associated with survival \\\u003C12 months\n7. Needs repeated MRI scans\n8. Requires diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT)\n9. Has an electrical or electromagnetic implant (e.g., cochlear prosthesis, pacemaker, neurostimulator, etc.) or plans to obtain, an active implanted medical device (AIMD) and\u002For an implanted medication pump (e.g., DUOPA™ infusion pump) and\u002For is treated with a portable infusion pump for any indication\n10. Is on anticoagulant therapy which cannot be paused for \\>5 days before surgery\n11. A history of cranial surgery including ablation procedure or any other previous neurosurgical procedure for the treatment of PD symptoms on either side of the brain\n12. Is currently participating in another clinical study (excluding any sub-study of the present trial). The sponsor will not grant waivers or protocol exceptions to any inclusion or exclusion criteria. Safety of subjects is the utmost concern and will be prioritized at every stage throughout this protocol.",{"count":96,"type":22},104,[98],"NA","The goal of this prospective, multi-center, randomized, double-blind, crossover clinical trial is to evaluate the effectiveness and safety of adaptive DBS (aDBS) and conventional DBS (cDBS) delivered through the AlphaDBS system, in levodopa-responsive Parkinson's disease subjects. Data from previous studies conducted in Europe indicate that the use of the AlphaDBS system is safe and effective in both aDBS and cDBS modes. However, such studies suggest that aDBS may lead to more ON-time without troublesome dyskinesias in some patients. The study is designed to first demonstrate safety of effectiveness of cDBS, then to directly compare effectiveness of aDBS relative to cDBS. Subjects enrolled in the study will undergo multiple visits to assess the improvement of PD symptoms and will be randomized to Mode 1 for three months, followed by Mode 2. At the end of Mode 2, subjects will select their preferred mode, which will be maintained for 3 additional months. Subjects will complete patient diaries at different time points to evaluate their symptoms throughout the day.",[32],[102,28,103,104,105,106],"Deep Brain Stimulation","adaptive Deep Brain Stimulation","aDBS","conventional Deep Brain Stimulation","cDBS","NOT_YET_RECRUITING","2026-04-02",{"date":110,"type":48},"2026-04-08",{"date":112,"type":22},"2026-08",{"date":114,"type":22},"2029-08",{"name":116,"class":55},"Newronika",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":126,"briefSummary":127,"conditions":128,"keywords":129,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100418633","video-oculography-and-parkinsons-disease-100418633","NCT04731246","Video-oculography and Parkinson's Disease","Video-oculography and Parkinson's Disease: A Prospective Study","\\*Inclusion Criteria:\n\n1. Male or Female;\n2. Clinically defined idiopathic Parkinson's Disease (PD);\n3. Brain MRI performed in routine care in the 12 months preceding inclusion;\n4. Cerebral DaTSCAN or cerebral PET with F-DOPA, performed as routine care before inclusion (no time limit), confirming presynaptic dopaminergic denervation;\n5. Hoehn \\& Yahr score: 1 to 3;\n6. Normal clinical examination of oculomotricity (slight impairment of smooth pursuit accepted);\n7. Neuro-cognitive disorders: absent or minor (according to DSM5);\n8. Sufficient written and oral expression in French;\n9. Covered by a health insurance system;\n10. Written informed consent signed by the patient;\n11. Presence of a caregiver.\n\n    \\* Exclusion Criteria:\n12. Psychiatric comorbidity (except anxiety or mild to moderate depression);\n13. Neurological comorbidity, if significant;\n14. Brain MRI showing:\n\n    1. significant cerebrovascular pathology (Fazekas I admitted),\n    2. another brain disease, including stroke.\n15. Major cognitive impairment;\n16. Absolute exclusion criteria and \"Red flags\" of the 2015 criteria orienting towards another degenerative pathology of the extrapyramidal system:\n\n    * Cerebellar syndrome\n    * Vertical oculomotricity disorders on clinical examination\n    * Motor symptoms restricted to the lower limbs\n    * Bilateral and perfectly symmetrical parkinsonism\n    * Early dystonia\n    * Clinical profile suggestive of behavioral variant frontotemporal dementia (bvFTD)\n    * Progressive aphasia or apraxia\n    * Moderate or severe postural instability and \u002F or early falls\n    * Early bulbar dysfunction (dysarthria, swallowing disorders)\n    * Ventilatory dysfunction (inspiration)\n    * Severe dysautonomia\n    * DOPA-resistance\n    * Neuroleptic treatment or related\n17. Normal MIBG myocardial scintigraphy (if performed).",{"count":125,"type":22},30,[98],"This study aims to study, in patient with Parkinson's disease, mild to moderate stage (according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease, Postuma et al., 2015):\n\n* the evolution of oculomotricity markers over time.\n* the correlation between neurological evaluations (motor and non-motor scores), neuropsychological evaluations (cognitive disorders) and oculomotricity evaluation, over a follow-up period of 7 years.\n* the impact of antiparkinsonian drugs on the evolution of oculomotricity assessment by video-oculography.\n* the value of oculomotricity assessment by video-oculography as an evolutionary marker of the disease.",[32],[43,130,131,132,133,134,135,136],"Video-oculography","Oculomotor disorders","Oculomotricity","Neuropsychological evaluations","Movement disorder","Motor disorders","Non-motor fluctuations","2025-09-30",{"date":139,"type":48},"2025-10-01",{"date":141,"type":48},"2021-07-07",{"date":143,"type":22},"2032-01",{"name":145,"class":85},"Association de Recherche Bibliographique pour les Neurosciences",1,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":156,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":4},"100600233","integration-of-augmented-visual-feedback-in-action-observation-and-motor-imagery-therapy-for-parkinsons-disease-100600233","NCT07094828","Integration of Augmented Visual Feedback in Action Observation and Motor Imagery Therapy for Parkinson's Disease","Integration of Augmented Visual Feedback Into Action Observation and Motor Imagery Therapy for Parkinson's Disease: A Randomized Controlled Trial","Inclusion Criteria:\n\n* diagnosis of idiopathic Parkinson's disease for at least 5 years;\n* stable medication regimen for at least 4 weeks;\n* no cognitive impairment according to the Mini-Mental State Examination;\n* at stage ≤3 on the Hoehn \\& Yahr scale;\n* provide informed consent to participate.\n\nExclusion Criteria:\n\n* undergoing advanced therapies (e.g., deep brain stimulation or infusion pump therapy);\n* unable to walk independently for at least 5 meters without assistive devices;\n* substance abuse;\n* with visual, orthopedic, or other medical conditions that could hinder the execution of activities;\n* history of other neurological disorders (other than Parkinson's disease).",{"count":155,"type":22},86,[98],"Improving movement control during rehabilitation is still a challenge for people with Parkinson's Disease, mainly because of the motor symptoms caused by the condition. However, new technologies offer promising ways to support therapy.\n\nThis clinical trial will test whether using TecnoBody® D-Wall technology integrated with two techniques (Action Observation and Motor Imagery) can improve physiotherapy outcomes for people with Parkinson's Disease.\n\nThe TecnoBody® D-Wall is a type of digital mirror that includes a 3D camera, pressure-sensitive platforms, and a screen. It shows a person's body movements in real time and gives visual feedback on joint mobility, balance, and how weight is distributed during movement.\n\nAction Observation and Motor Imagery are two techniques already used in physiotherapy. Action Observation involves watching someone perform a movement, while Motor Imagery involves mentally rehearsing the movement before doing it. Studies have shown that both techniques activate the same brain areas involved in actual movement.\n\nIn this trial, after watching and imagining the movement, participants will perform the exercise in front of the D-Wall. This setup gives them real-time feedback to help improve how they move, a new approach for these techniques.\n\nTo see if this approach works, we will measure balance using a test validated for people with Parkinson's Disease and assess mobility using lab-based gait analysis, which tracks how a person walks.\n\nParticipants in the study will:\n\n* Be receiving routine physiotherapy at a hospital that is specialized in Parkinson's Disease rehabilitation.\n* Be randomly assigned to one of two groups: 1) One group will receive physiotherapy incorporating the D-Wall alongside Action Observation and Motor Imagery; 2) The other group will receive physiotherapy incorporating the D-Wall but, without Action Observation or Motor Imagery.\n* Take part in therapy for up to four weeks, followed by another four weeks of monitoring, for a total of up to two months.\n* Complete some initial tests to check if they are eligible for the study.\n\nThis study includes patients who have been diagnosed with idiopathic Parkinson's Disease and are undergoing rehabilitation as part of their usual hospital care. The intervention lasts as long as their regular hospital stay.",[32],[160,161,162,163,164],"Action Observation","Motor Imagery","Technology","Physiotherapy","Gait Analysis","2025-07-23",{"date":167,"type":48},"2025-07-30",{"date":169,"type":22},"2025-09-01",{"date":171,"type":22},"2026-07",{"name":173,"class":85},"University of Bergamo",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":181,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":188,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":146},"100594998","the-impact-of-deep-brain-stimulation-on-speech-and-swallow-function-in-parkinson-disease-100594998","NCT07026734","The Impact of Deep Brain Stimulation on Speech and Swallow Function in Parkinson Disease","Effects of Deep Brain Stimulation (DBS) on Laryngeal Function and Associated Behaviors in Parkinson Disease","Inclusion Criteria:\n\nDiagnosis of idiopathic (non-genetic\u002Ffamilial) PD made by fellowship-trained neurologist by applying strict UK brain bank criteria\n\nHoehn \\& Yahr staging I - IV\n\nApproved for DBS surgery to either STN or GPi, with NO existing DBS electrodes.\n\nMild or moderate voice \u002F swallow problems\n\nExclusion Criteria:\n\nNeurological disorder(s) other than PD (including essential tremor) Severe neuropsychological dysfunction, unstable psychiatric disease at the discretion of the treating neurologist\u002Fpsychiatrist (i.e., severe depression) or moderate to severe cognitive impairment.\n\nHistory of:\n\n* Head, neck, or lung cancer (except minor squamous cell skin cancers)\n* Structural, functional, or neurologic voice disorder unrelated to PD\n* Chronic refractory cough\n* Bleeding disorder","45 Years","85 Years",{"count":184,"type":22},100,[98],"Nearly one-million people in North America are now living with Parkinson's disease (PD), and that number is projected to rise to nearly 1.2 million by 2030. With advancements in neuromodulatory technologies, increasingly more of these individuals elect to undergo deep brain stimulation (DBS) surgery in order to control symptoms of the disease, including refractory tremor, medication-induced dyskinesias, and PD-associated dystonia. The two most common DBS neural targets for controlling these symptoms are the globus pallidus internal segment (GPi) and the subthalamic nucleus (STN). Recent meta-analyses have shown relative equivalence between these two sites at controlling core PD symptoms. To date, there is not conclusive evidence regarding the potential impact of DBS to GPi or STN on laryngeal-mediated functions of voice, swallowing, and cough, and consequently no guidance on whether these outcomes should be considered when selecting DBS target. Therefore, the goal of this project is to determine the impact of DBS neural target (STN versus GPi), lead location within the target, laterality, and stimulation settings on voice, swallow and cough function in people with PD. The larynx is an important player in each of these functions, and our central hypothesis is that spread of stimulation to corticobulbar fibers in the genu of the internal capsule have deleterious effects on laryngeal motor control, resulting in voice, swallow, and cough dysfunction. We have identified three specific aims for this application: 1.) To compare laryngeal function during volitional voice tasks pre-post DBS, and when DBS placement is bilateral versus unilateral for STN and GPi targets. 2.) To compare laryngeal function during volitional and induced cough tasks pre-post DBS, and when DBS placement is bilateral versus unilateral for STN and GPi targets. 3.) To compare airway safety associated with laryngeal onset, degree, and duration of maximum closure during swallowing, pre-post DBS, and when DBS placement is bilateral versus unilateral for STN and GPi targets. These hypotheses were developed based on compelling published and unpublished preliminary data. We will accomplish these aims by enrolling people with PD who are being considered for DBS surgery. We will measure physiologic, functional, and quality of life parameters of voice, swallow and cough pre- and post-surgically. The realization of the proposed aims is significant because it will address a substantial gap in our understanding of DBS outcomes related to communication and airway protection, which are important in terms of morbidity, mortality, and quality of life for patients with PD. The translational potential to provide additional guidance to DBS surgical teams regarding whether voice, swallow or cough functions should be considered with selecting DBS target and\u002For laterality is high. Ultimately, the project fits squarely within the overarching goal of the research team to deliver the best possible care to people with PD.",[32],[189,190,191,192,193],"Parkinson disease","Deep brain stimulation","voice","speech","swallow","2025-07-18",{"date":196,"type":48},"2025-07-24",{"date":198,"type":48},"2025-05-26",{"date":200,"type":22},"2029-05",{"name":202,"class":85},"University of Florida",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":182,"enrollmentInfo":211,"targetDuration":4,"studyType":23,"phases":213,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":227,"leadSponsor":229,"locationsCount":146},"100570305","mediterranean-diet-effects-on-parkinsons-disease-100570305","NCT06705517","Mediterranean Diet Effects on Parkinson's Disease","Mediterranean Diet Effects on Parkinson's Disease (MED-PARK): a Randomized Controlled Trial","MED-PARK","Inclusion Criteria:\n\n1. PD diagnosis according to international guidelines;\n2. Age between 40 and 85 years;\n3. Naive to medication or with a stable dosage of anti-Parkinson's therapy for at least two weeks;\n4. Hoehn \\& Yahr stage ≤3;\n5. Normal independent feeding;\n6. Ability to complete informed consent;\n7. Willingness to maintain the usual diet in the period between T0 and T1;\n8. Willingness to maintain the usual diet if randomized to the control group in the T1-T2 period;\n9. Willingness to make changes in their diet to follow a Mediterranean diet if randomized to the intervention group in the T1-T2 period;\n10. Willingness to fill out questionnaires;\n11. Willingness to provide blood samples during the study collection periods;\n12. Willingness to provide stool samples during the study collection periods;\n13. Willingness to fast (without food or drink except water, tea or coffee) at least 12 hours before each sample collection;\n14. Willingness to discontinue taking supplements, probiotics, herbal or high- dose vitamins or minerals that could impact inflammation during the period between T0 and T1 and for the duration of the study protocol;\n15. No medical and\u002For social conditions that could interfere with participation in a six-month interventional study.\n\nExclusion Criteria:\n\n1. Atypical or secondary parkinsonism;\n2. Underweight (\\\u003C18.5);\n3. Obesity (BMI\\>30);\n4. Pregnancy or suspected pregnancy;\n5. Normal assisted nutrition;\n6. Enteral nutrition;\n7. Chronic autoimmune diseases;\n8. Chronic use of immunosuppressive drugs in the past year;\n9. Chronic use of cytotoxic cancer drugs in the past year;\n10. Major abdominal surgeries;\n11. Concurrent participation in other interventional studies;\n12. Intentional change in diet after PD diagnosis.",{"count":212,"type":22},44,[98],"Currently, there are no disease-modifying treatments for Parkinson's disease (PD), the second most common neurodegenerative disorder worldwide, making it crucial to find interventions that can change the disease's trajectory. Epidemiological studies suggest that the Mediterranean diet (MD) is linked to improved motor and non-motor symptoms, slower disease progression, and lower mortality in PD patients. However, few interventional studies have explored this connection. This study assesses whether an MD can improve motor and non-motor symptoms in PD patients. Additionally, the study will examine the effects of the diet on a patient's quality of life, gastrointestinal symptomatology, adaptive immune system, fecal and nasal microbiome, and fecal and urinary metabolomics.\n\nThis is a randomized, controlled, non-pharmacological, single-center, masked trial with two parallel groups. It will evaluate the safety and efficacy of the MD on motor and non-motor symptoms reported by PD patients. Forty-four participants, aged 40-85, meeting the inclusion criteria will be enrolled and block-randomized into two groups: one maintaining their usual diet (control) and the other following a MD for six months (intervention).\n\nThe primary outcome is patient-reported symptoms, measured using the MDS-UPDRS I+II score.\n\nSecondary outcomes include the analysis of adaptive immune system cells, nasal and fecal microbiome composition, and inflammatory and metabolic markers. Additional assessments include disease severity (MDS-UPDRS), non-motor symptoms (Non-Motor Symptoms Scale), participant well-being (36-Item Short Form Health Survey), gastrointestinal symptoms (Gastrointestinal Symptom Rating Scale and Patient Assessment of Constipation Quality of Life), and the intensity of dopaminergic therapy (levodopa equivalents). Evaluations will be performed at baseline and after six months.",[29,28,32,216],"PARKINSON DISEASE (Disorder)",[218,219,29,189,220,221,222],"Diet","Mediterranean Diet","MIND diet","plant based diet","unprocessed diet","2025-07-08",{"date":225,"type":48},"2025-07-11",{"date":50,"type":48},{"date":228,"type":22},"2026-09",{"name":230,"class":85},"Università degli Studi dell'Insubria",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":23,"phases":240,"briefSummary":241,"conditions":242,"keywords":243,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":252,"locationsCount":254},"100598028","smart-pd-evaluating-the-impact-of-smartphone-based-wearable-technology-on-motor-symptoms-and-quality-of-life-in-people-with-parkinsons-disease-100598028","NCT07066163","SMART-PD: Evaluating the Impact of Smartphone-Based Wearable Technology on Motor Symptoms and Quality of Life in People With Parkinson's Disease","SMART PD","Inclusion criteria:\n\n* Meet criteria for Parkinson's disease using MDS Clinical Diagnostic Criteria for Parkinson's Disease\n* Presence of Motor fluctuations based on movement disorder neurologist assessment.\n* Motor ability to use the wearable device and access the wearable device application.\n* Cognitively ability to do ADL's and use the wearable device and access the wearable device application based on clinician's judgment.\n* Knowledge of English to enter medication details in the wearable device application.\n\nExclusion criteria:\n\n* Physical barriers in using the wearable device.\n* Atypical Parkinsonian disorder or other causes of Parkinsonism\n* Inability to read or write English.",{"count":239,"type":22},32,[98],"This study aims to evaluate whether wearable technology can improve the management of motor symptoms in people with Parkinson's disease (PD) who experience motor fluctuations throughout the day. The project will use a smartwatch and mobile app (KinesiaU) to continuously track movement, allowing for more responsive and personalized treatment compared to traditional monitoring methods.\n\nIn this pilot randomized controlled trial, 32 participants will be assigned to either:\n\nA control group receiving standard care, or\n\nA wearable device group receiving standard care plus using the smartwatch.\n\nOutcomes will be assessed over a 4-week period, focusing on changes in motor function, quality of life, and self-management. The study will also examine feasibility, adherence, and data quality.\n\nIf successful, this trial will provide critical evidence for integrating wearable devices into routine clinical care for PD, paving the way for larger efficacy trials and more patient-centered care strategies.",[32],[244,245],"parkinson","wearable","2025-07-03",{"date":248,"type":48},"2025-07-15",{"date":250,"type":22},"2026-01",{"date":200,"type":22},{"name":253,"class":85},"Western University",2,{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":17,"minAge":261,"maxAge":182,"enrollmentInfo":262,"targetDuration":4,"studyType":23,"phases":264,"briefSummary":265,"conditions":266,"keywords":267,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":146},"100582147","step-up-to-pd-a-community-based-walking-program-for-people-with-parkinsons-disease-100582147","NCT06859528","Step Up to PD: A Community-based Walking Program for People With Parkinson's Disease","Inclusion Criteria:\n\n* 30-85 years old\n* Neurologist-diagnosed Parkinson's disease\n* Able to walk independently with or without a walking aid (e.g., cane, walker)\n* Willing to participate in study for at least 6 months\n\nExclusion Criteria:\n\n* Health diagnosis that would limit exercise participation (e.g., heart problems, uncontrolled blood pressure, exercise-induced asthma).\n* Additional neurologic disease or injury beyond Parkinson's disease.\n* Evidence of significant cognitive impairment. This will be determined by completing the Montreal Cognitive Assessment\n* Participants with poor walking ability (determined using the Timed Up and Go Test during initial testing).","30 Years",{"count":263,"type":22},40,[98],"This study will investigate the feasibility of a 6-month community walking program for people with Parkinson's disease (PD) and their care partners in greater Saint Louis, Missouri region. The walking program will consist of weekly, organized walking groups at the Missouri Botanical Gardens. Participants in the program will use Nordic walking poles during the walks. The walking group(s) will meet once per week and will be supervised by walking group leaders from Saint Louis University. Participants will be given a smart watch to wear that will help step counts will be tracked in real-time. The program is designed to get people with Parkinson's disease out of their homes, cultivate a culture of connection with others with Parkinson's disease, and to be collectively accountable for a common goal toward increasing their physical and social engagement in their communities.",[28,32],[268,269,270,271],"Walking","Physical Activity","Social Connectedness","Loneliness","2025-05-12",{"date":274,"type":48},"2025-05-14",{"date":276,"type":48},"2025-04-01",{"date":278,"type":22},"2027-09-30",{"name":280,"class":85},"St. Louis University",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":291,"briefSummary":292,"conditions":293,"keywords":294,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":146},"100584723","strength-endurance-circuit-training-in-parkinsons-disease-100584723","NCT06893055","Strength-Endurance Circuit Training in Parkinson's Disease","Strength-Endurance Circuit Training in Parkinson's Disease: Effects on Disease Severity, Physical Performance, Blood Biomarkers and Quality of Life.","Inclusion Criteria:\n\n* age ≥18 years\n* diagnosis of idiopathic Parkinson´s disease\n* Hoehn-Yahr Scale ≤ 2,5\n* stable dopaminergic medication\n\nExclusion Criteria:\n\n* age ≥75 years\n* Hoehn-Yahr Scale ≥ 2,5\n* deep brain stimulation\n* presence of freezing\n* Camptocormia\n* inability to walk without support\n* inability to perform study procedures\n* limiting co-morbidities\n* attendance at training sessions below 70%","75 Years",{"count":290,"type":22},90,[98],"The goal of this clinical trial is to determine whether adding strength training to aerobic training has a comparable or greater effect on the clinical status of Parkinson's disease patients than a standalone aerobic training.\n\n\\- Does combined strength-endurance circuit training provide added benefits to physical performance, disease severity, blood biomarkers, and quality of life in PD patients compared to standalone aerobic training?\n\nParticipants will:\n\n* undergo outcome measurements before and after the 12-week intervention and a 3-month follow-up measurement,\n* visit the clinic twice a week for 1-hour training sessions.\n* selected patients will be given a smartwatch with a pedometer that will count their average number of steps before, during and after the training period",[32],[28,295,296,163,297,298,299],"Strength training","Endurance training","Irisin","Quality of Life","Physical performance","2025-04-07",{"date":302,"type":48},"2025-04-09",{"date":304,"type":48},"2025-03-03",{"date":306,"type":22},"2027-03",{"name":308,"class":85},"General University Hospital, Prague",{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":23,"phases":317,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":4},"100577974","phase-4-vortioxetine-for-depressive-symptoms-and-freezing-of-gait-in-parkinson-disease-100577974","NCT06805266","Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease","An Open Study to Evaluate the Efficacy of Vortioxetine on Freezing of Gait in Patients Affected by Parkinson Disease with Depressive Symptoms","Inclusion Criteria:\n\n1. Diagnosis of PD according to published criteria\n2. Occurrence of depression according to Beck Depression Inventory II (score ≥ 15)\n3. A score ≥ 2 on the freezing question #2.13 of part 2 of the MDS-UPDRS (moderate-severe FOG).\n4. FOG not responsive to dopaminergic treatment.\n\nExclusion Criteria:\n\n1. Treatment with IMAO-B (rasagiline, selegiline, safinamide) (to be included, IMAO-B need to be withdrawn for at least 15 days)\n2. Concomitant treatment with other antidepressant drugs\n3. Hepatic and renal insufficiency\n4. Treatment with tramadol or triptans\n5. Psychotic disorder\n6. Dementia according to DSM-V",{"count":263,"type":22},[318],"PHASE4","The present study involves patients with Parkinson Disease (PD) suffering from freezing of gait (FOG) and depressive symptoms. The main aim of the study is evaluating the efficacy of vortioxetine in reducing moderate\u002Fsevere FOG not responsive to dopaminergic treatment in patients with PD with depressive symptoms.",[32,72,321],"Depression Not Otherwise Specified",[28,323,324],"freezing of gait","depression NOS","2025-02-03",{"date":327,"type":48},"2025-02-06",{"date":329,"type":22},"2025-02",{"date":331,"type":22},"2027-02",{"name":333,"class":85},"Marianna Amboni",{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":17,"minAge":342,"maxAge":288,"enrollmentInfo":343,"targetDuration":4,"studyType":23,"phases":345,"briefSummary":346,"conditions":347,"keywords":348,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":146},"100567202","neuroprotective-effects-of-long-term-tavns-in-early-parkinsons-disease-patients-100567202","NCT06665113","Neuroprotective Effects of Long-term TaVNS in Early Parkinson's Disease Patients","A Double-blinded, Randomized, Parallel-group, Superiority Study to Explore the Neuroprotective Effects of Long-term Transcutaneous Auricular Vagus Nerve Stimulation(taVNS) in Early Parkinson's Disease(PD) Patients","NLTVNSPD","Inclusion Criteria:\n\n1. Age 55-75 years.\n2. Clinically diagnosed Idiopathic Parkinson's disease patients according to the 2016 Chinese diagnostic criteria for Parkinson's disease.\n3. Hoehn and Yahr (H\\&Y) stage ≤ 2.5 at medication initiation.\n4. Parkinson's disease duration ≤ 3 years.\n5. Receiving standard anti-Parkinson's disease medication treatment.\n\nExclusion Criteria:\n\n1. Patients with cognitive impairment (MMSE \\\u003C 24 and\u002For MoCA \\\u003C 26) or mental illnesses, or those unable to cooperate for other reasons.\n2. Use of neuroprotective medications within 90 days prior to baseline, including monoamine oxidase B inhibitors (rasagiline, selegiline), certain dopamine receptor agonists (ropinirole), and GLP-1 receptor agonists such as Exenatide and NLY-01.\n3. Use of any medications that may affect dopamine metabolism and\u002For dopamine receptors within 90 days prior to baseline, including typical and atypical antipsychotics, metoclopramide, α-methyl-dopa, flunarizine, apomorphine, amphetamine derivatives, bupropion, buprenorphine, cocaine, meperidine, methamphetamine, norephedrine, phentermine, modafinil, methylphenidate, procyclidine, reserpine, phenylpropanolamine, or MAO-A inhibitors.\n4. Previous treatment with vagus nerve stimulation.\n5. MRI contraindications (e.g., claustrophobia unresponsive to comfort or low-dose anxiolytics, dental implants) or MRI scans indicating clinically significant abnormalities in the brain, including but not limited to past hemorrhages or infarcts \\> 1 cm³ or \\> 3 lacunar infarcts.\n6. Contraindications for taVNS, such as patients with cardiac pacemakers or a history of DBS surgery, or those planning surgery during the trial; ear conditions, such as tympanic membrane perforation.\n7. Atypical or secondary Parkinsonian syndromes, including but not limited to those caused by trauma, brain tumors, infections, cerebrovascular diseases, or other neurological disorders, or symptoms confirmed by the investigator as drug, chemical, or toxin-related.\n8. Previous history of stroke or intracranial mass lesions.\n9. Patients with existing or potential cardiovascular diseases.\n10. Ophthalmic diseases affecting eye movements.\n11. Any neurological disorders other than Parkinsonian motor symptoms that interfere with gait or balance (e.g., chronic pain) or musculoskeletal injuries (e.g., fractures, stroke sequelae).\n12. Severe organic diseases, such as late-stage tumors, with a life expectancy of less than 2 years.\n13. Concurrent participation in other clinical trials.\n14. Inability to receive the required treatment and follow-up due to geographic reasons.\n15. Any subject with an upper limb UPDRS tremor score of 3 or higher.\n16. Patients with a history of PD-related freezing episodes or falls.","55 Years",{"count":344,"type":22},12,[98],"This study is a randomized, double-blind, controlled trial exploring the effects of long-term taVNS intervention in patients with early-stage Parkinson's disease.",[32],[32,349],"Vagus Nerve Stimulation","2025-01-12",{"date":352,"type":48},"2025-01-14",{"date":354,"type":48},"2024-12-23",{"date":356,"type":22},"2026-06",{"name":358,"class":85},"Kezhong Zhang",{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":39,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":17,"minAge":365,"maxAge":288,"enrollmentInfo":366,"targetDuration":4,"studyType":23,"phases":367,"briefSummary":368,"conditions":369,"keywords":370,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":379,"leadSponsor":381,"locationsCount":146},"100572192","a-novel-robotic-system-for-motor-cognitive-exercise-for-patients-with-parkinsons-disease-100572192","NCT06730074","A Novel Robotic System for Motor-cognitive Exercise for Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Signing the informed consent form\n* Men and women in ages 50-75\n* Hebrew speakers\n* Have Idiopathic Parkinson's disease\n* Hoehn and Yahr 3 and below\n* Moca test 23 and above\n\nExclusion Criteria:\n\n* Patients with Parkinson's plus syndromes\n* PD patients who suffer from unrelated neurological symptoms.\n* Orthopedic problems of the upper limb\n* Recent surgery conducted on the upper limb\n* Uncorrected vision problems\n* Uncorrected severe hearing loss","50 Years",{"count":5,"type":22},[98],"The objective of this study is to test a gamified rehabilitation system in a sitting position involving robots and music for the benefit of individuals with Parkinson's disease (PD). This pilot experiment will involve the collection of both subjective user evaluation measures and objective motor and cognitive measures.",[32],[371,372,373,374,39],"Parkinson-disease","SAR","Rehabilitation","Motor-Cognitive","2024-12-12",{"date":377,"type":48},"2024-12-17",{"date":375,"type":48},{"date":380,"type":22},"2025-08",{"name":382,"class":85},"Adi Negev-Nahalat Eran",{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":288,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":391,"briefSummary":392,"conditions":393,"keywords":395,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":4},"100564009","ameliorating-effects-and-mechanisms-of-tavns-on-constipation-in-pd-patients-100564009","NCT06623591","Ameliorating Effects and Mechanisms of TaVNS on Constipation in PD Patients.","Ameliorating Effects and Mechanisms of Transcutaneous Auricular Vagus Nerve Stimulation on Constipation in Parkinson's Disease Patients: a Randomized, Double-blind Clinical Trial","Inclusion Criteria:\n\n1. aged 40-70 years;\n2. had a PD diagnosis designated by movement disorder neurologists (Ke-zhong Zhang and Yong-sheng Yuan) according to Movement Disorder Society Clinical Diagnostic Criteria;\n3. fulfilled Rome IV criteria for functional constipation, including having \\\u003C 3 spontaneous bowel movements (SBM; i.e., not induced by rescue medication) per week for the past 3 months with symptom duration of at least 6 months;\n4. stable initiation of PD medications, leastways 3 month before this investigation; (5) provided written informed consent.\n\nExclusion Criteria:\n\n1. a history of previous abdominal surgery (other than appendectomy);\n2. the presence of carcinoma;\n3. any organic diseases causing constipation or neurologic diseases such as multiple sclerosis, rachischisis, or spinal cord injury;\n4. taking antidepressant agents including tricyclic antidepressants and selective serotonin reuptake inhibitors;\n5. a serious concomitant disease of the heart, liver, kidney, or diabetes;\n6. pregnancy or lactation;\n7. participating in another trial or enrolled in a trial during the past month;\n8. an allergic reaction to surface electrodes.",{"count":125,"type":22},[98],"The investigators intend to conduct a randomized, double-blind, sham-stimulation-controlled experiment, incorporating various clinical scales, gastrointestinal electrogram, and high-resolution anorectal manometry (HRAM), to investigate the improvement effect of taVNS on constipation symptoms in PD patients.",[32,394],"Constipation",[396,397],"constipation","Parkinson's disease","2024-10-03",{"date":400,"type":48},"2024-10-04",{"date":402,"type":22},"2024-10-15",{"date":404,"type":22},"2024-12-30",{"name":358,"class":85},{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":412,"minAge":66,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":23,"phases":415,"briefSummary":416,"conditions":417,"keywords":418,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":4},"100560888","vibrotactile-coordinated-reset-for-parkinsons-patients-who-are-on-dopaminergic-medication-100560888","NCT06583005","Vibrotactile Coordinated Reset for Parkinsons Patients Who Are on Dopaminergic Medication","Inclusion Criteria:\n\n* Age at the time of enrollment: Adults 18 and older\n* Idiopathic Parkinson's Symptoms between Hoehn and Yahr stages 2 to 4\n* Fluent in English\n* Comfortable with technology; can use a computer, check email, and access the internet; can initiate and engage in a virtual meeting for training and monitoring purposes.\n* Lives in the United States\n\nExclusion Criteria:\n\n* Any significant neuro-psychiatric problems, including acute confusional state, ongoing psychosis, or suicidal tendencies.\n* Any current drug or alcohol abuse.\n* Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days. Any other trial participation should be approved by the Principal Investigators.\n* Pregnancy, breast-feeding or wanting to become pregnant.\n* Patient is unable to communicate properly with staff (i.e., severe speech problems).\n* Excessive drooling","FEMALE",{"count":414,"type":22},20,[98],"The purpose of this clinical trial is to test the efficacy of vibrotactile coordinated reset stimulation to improve movement ability and other symptoms of human subject participants with Parkinsons Disease who take dopaminergic medication and are unable to withhold this medication. Participants will be followed for five years and make a total of five study visits.",[32],[419,420,421],"vibrotactile","vibrotactile coordinated reset","parkinsons disease","2024-08-31",{"date":424,"type":48},"2024-09-03",{"date":426,"type":22},"2025-02-15",{"date":428,"type":22},"2027-05-15",{"name":430,"class":85},"Stanford University"]